drugset / Trial / NCT06922890
First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury
Non-randomizedSequentialOpen-labelTreatment
Summary
This study aim to investigate the safety and exploratory efficacy of STUP-001 which is AAV-based spinal cord injury investigational product.
Timeline
- Start
- 2025-07-30
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STUP-001 | Gene therapy (AAV / viral vector) | 0.025 ml | Other |
| Subject | STUP-001 | Gene therapy (AAV / viral vector) | 0.05 ml | Other |